[시장보고서]이식 진단 시장 규모, 점유율과 동향 분석 리포트 : 검사별, 제품별, 용도별, 이식 부위별, 최종 용도별, 지역별, 부문 예측(2025-2033년)

이식 진단 시장 규모, 점유율과 동향 분석 리포트 : 검사별, 제품별, 용도별, 이식 부위별, 최종 용도별, 지역별, 부문 예측(2025-2033년)

Transplant Diagnostics Market Size, Share & Trends Analysis Report By Test, By Product, By Application, By Transplant Area, By End-use, By Region, And Segment Forecasts, 2025 - 2033

상품코드 : 1869713

리서치사 : Grand View Research

발행일 : 2025년 10월

페이지 정보 : 영문 150 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,950

￦ 8,845,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950

￦ 10,332,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950

￦ 13,305,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

이식 진단 시장 요약

세계의 이식 진단 시장 규모는 2024년에 63억 9,000만 달러로 추정되며, 2033년에는 121억 5,000만 달러에 달할 것으로 예측됩니다.

2025-2033년에 CAGR 7.45%로 성장할 전망입니다. 유전성 질환의 유병률 증가, 유전자 검사 기술의 발전, 맞춤형 의료에 대한 인식과 수요 증가가 시장 성장을 촉진하고 있습니다.

예를 들어 2025년 10월에는 UBC 효소 기술이 이식용 유니버설 공여 장기를 위한 첫 번째 인체 실험을 도입했습니다. 이 회사는 신장을 이식 가능한 범용 O형으로 변환하는 효소를 개발하여 보다 신속하고 적합한 장기 기증을 위한 중요한 발걸음을 내딛었습니다. 또한 이 신장은 초급성 거부반응의 징후 없이 2일 동안 정상적으로 기능한 것으로 확인되었습니다. 이 빠른 면역 반응은 몇 분 안에 부적합한 장기를 파괴할 수 있습니다. 3일째에는 일부 혈액형 마커가 다시 나타나 중등도의 반응을 일으켰습니다. 그러나 손상은 일반적인 부적합보다 훨씬 경미했으며, 조사 결과 신체가 장기를 견디기 시작했다는 징후가 확인되었습니다.

또한 고령화 사회의 진전, 만성질환의 확산, 이식기술의 발전이 시장 성장을 촉진하고 있습니다. 예를 들어 2025년 10월 세계보건기구(WHO)는 2020년 60세 이상 인구가 5세 미만 아동 수를 넘어섰다고 발표했습니다. 2015-2050년까지 60세 이상 인구는 전 세계에서 12%에서 22%로 거의 두 배로 증가할 것으로 예측됩니다. 또한 2050년까지 고령자의 80%가 중저소득 국가에 거주할 것으로 예측되고 있습니다. 인구 고령화 속도는 과거에 비해 눈에 띄게 빨라지고 있습니다. 심부전, 신장질환, 간질환 등 만성질환이 지속적으로 증가하면서 생명을 살리는 치료로서 장기이식의 필요성도 높아지고 있습니다. 이러한 이식 수술 증가는 기증자와 수혜자의 적합성을 보장하고, 장기 거부반응의 위험을 줄이고, 이식 성공률을 높이기 위해 정확하고 정교한 진단 툴의 중요성을 강조하고 있습니다.

시장 세분화와 범위
시장 계통 전망
- 모시장 전망
- 관련/보조 시장 전망
시장 역학
시장 성장 촉진요인 분석
- 유전성 질환의 유병률 상승
- 유전자 검사에서 기술의 진보
- 맞춤형 의료에 대한 의식과 수요 증가
시장 성장 억제요인 분석
- 공중위생 검사 한정적인 시행
Porter's Five Forces 분석
PESTLE 분석
파이프라인 분석

제4장 이식 진단 시장 : 검사 추정·동향 분석

이식 진단 시장 : 검사 변동 분석
분자 어세이
- PCR 기반 분자 어세이
- 실시간 PCR
- 시퀀스 기반 프라이머 PCR
- 배열 특이적 올리고뉴클레오티드 PCR
- 기타 PCR 기반 분자 어세이
시퀀싱 기반 분자 어세이
- 생어 시퀀싱
- 차세대 시퀀싱
- 기타 시퀀싱 기반 분자 어세이
비분자 어세이
- 혈청학적 검사
- 혼합 림프구 배양 어세이

제5장 이식 진단 시장 : 제품 추정·동향 분석

이식 진단 시장 : 제품 변동 분석
시약과 소모품
기기
소프트웨어와 서비스

제6장 이식 진단 시장 : 용도 추정·동향 분석

이식 진단 시장 : 용도 변동 분석
진단 용도
- 감염증 검사
- 조직 적합성 검사
- 혈액 프로파일링
연구 용도

제7장 이식 진단 시장 : 이식 부위 추정·동향 분석

이식 진단 시장 : 이식 부위 변동 분석
고형 영역 이식
- 신장 이식
- 간이식
- 심장이식
- 폐이식
- 췌장 이식
- 기타 장기 이식
줄기세포 이식
- 연부조직 이식
- 골수 이식

제8장 이식 진단 시장 : 최종 용도 추정·동향 분석

이식 진단 시장 : 최종 용도 변동 분석
병원과 이식 센터
연구·학술기관
독립 표준실험실

제9장 이식 진단 시장 : 지역의 비즈니스 분석

지역 시장 스냅숏
북미
유럽
아시아태평양
라틴아메리카
중동 및 아프리카

제10장 경쟁 구도

기업 분류
전략 지도제작
- 신제품 발매
- 파트너십
- 취득
- 협업
- 자금조달
주요 기업 시장 점유율 분석, 2024년
기업 히트맵 분석
기업 개요
- Thermo Fisher Scientific, Inc.
- Illumina, Inc.
- F. Hoffmann La-Roche Ltd
- Abbott
- QIAGEN
- Bruker
- BD(Becton, Dickinson and Company)
- Werfen(Immucor, Inc.)
- Bio-Rad Laboratories, Inc.
- Omixon Inc.

KSA

영문 목차

영문목차

Transplant Diagnostics Market Summary

The global transplant diagnostics market size was estimated at USD 6.39 billion in 2024 and is expected to reach USD 12.15 billion in 2033, growing at a CAGR of 7.45% from 2025 to 2033. The rising prevalence of genetic disorders, technological advancements in genetic testing, and growing awareness and demand for personalized medicine are boosting the market growth.

For instance, in October 2025, UBC enzyme technology introduced the first human test toward universal donor organs for transplantation. It has developed enzymes that successfully convert a kidney to universal type O for transplant, marking a significant step toward faster, more compatible organ donations. Further, the results show that the kidney functioned normally for two days without evidence of hyperacute rejection. This quick immune reaction can destroy an incompatible organ in minutes. By the third day, some blood-type markers resurfaced, causing a moderate response. Still, the damage was significantly less severe than in a usual mismatch, and researchers noticed signals that the body was starting to tolerate the organ.

Furthermore, the aging population, the prevalence of chronic disease, and advances in transplantation techniques are all driving market growth. For example, in October 2025, the World Health Organization claimed that in 2020, individuals aged 60 and older outnumbered children under five. Between 2015 and 2050, the worldwide population over 60 will almost double, from 12% to 22%. Furthermore, by 2050, 80% of older people will reside in low- and middle-income countries. The pace of population ageing is much faster than in the past. As chronic diseases such as heart failure, kidney disease, and liver disorders continue to rise, the need for organ transplantation as a life-saving treatment is also increasing. This rise in transplant procedures highlights the importance of accurate and advanced diagnostic tools to ensure donor-recipient compatibility, reduce the risk of organ rejection, and improve transplantation success rates.

Global Transplant Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global transplant diagnostics market report based on test, product, application, transplant area, end-use, and region:

Test Outlook (Revenue, USD Million, 2021 - 2033)
- Molecular Assays
PCR-based Molecular Assays
Real-time PCR
Sequence-based Primer-PCR
Sequence-specific Oligonucleotide-PCR
Other PCR-based Molecular Assays
- Sequencing-based Molecular Assays
Sanger Sequencing
Next Generation Sequencing
Other Sequencing-based Molecular Assays
- Non-molecular Assays
Serological Assays
Mixed Lymphocyte Culture Assays
Product Outlook (Revenue, USD Million, 2021 - 2033)
- Reagents & Consumables
- Instruments
- Software and Services
Application Outlook (Revenue, USD Million, 2021 - 2033)
- Diagnostic Application
Infectious Disease Testing
Histocompatibility Testing
Blood Profiling
- Research Application
Transplant Area Outlook (Revenue, USD Million, 2021 - 2033)
- Solid Area Transplantation
Kidney Transplantation
Liver Transplantation
Heart Transplantation
Lung Transplantation
Pancreas Transplantation
Other Organs Transplantation
- Stem Cell Transplantation
- Soft Tissue Transplantation
- Bone Marrow Transplantation
End-use Outlook (Revenue, USD Million, 2021 - 2033)
- Hospitals and Transplant Centers
- Research and Academic Institutes
- Independent Reference Laboratories
Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
U.S.
- Canada
- Mexico
Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
Latin America
- Brazil
- Argentina
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait

Chapter 1. Transplant Diagnostics Market: Methodology and Scope

1.1. Market Segmentation and Scope
- 1.1.1. Segment Definitions
  - 1.1.1.1. Test
  - 1.1.1.2. Product Segment
  - 1.1.1.3. Application Segment
  - 1.1.1.4. Transplant Area Segment
  - 1.1.1.5. End Use Segment
1.2. Regional Scope
1.3. Estimates and Forecast Timeline
1.4. Objectives
- 1.4.1. Objective - 1
- 1.4.2. Objective - 2
- 1.4.3. Objective - 3
1.5. Research Methodology
1.6. Information Procurement
- 1.6.1. Purchased Database
- 1.6.2. GVR's Internal Database
- 1.6.3. Secondary Sources
- 1.6.4. Primary Research
1.7. Information or Data Analysis
- 1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
- 1.9.1. Commodity Flow Analysis
1.10. List of Secondary Sources
1.11. List of Abbreviations

Chapter 2. Transplant Diagnostics Market: Executive Summary

2.1. Market Snapshot
2.2. Test
2.3. Product Snapshot
2.4. Application Snapshot
2.5. Transplant Area Snapshot
2.6. End Use Snapshot
2.7. Competitive Landscape Snapshot

Chapter 3. Transplant Diagnostics Market Variables, Trends, & Scope

3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
- 3.2.1. Parent Market Outlook
- 3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers Analysis
- 3.4.1. Rising prevalence of genetic disorders
- 3.4.2. Technological advancements in genetic testing
- 3.4.3. Growing awareness and demand for personalized medicine
3.5. Market Restraint Analysis
- 3.5.1. Limited implementation of public health screening
3.6. Porter's Five Forces Analysis
3.7. PESTLE Analysis
3.8. Pipeline Analysis

Chapter 4. Transplant Diagnostics Market: Test Estimates & Trend Analysis

4.1. Transplant Diagnostics Market: Test Movement Analysis
4.2. Molecular Assays
- 4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.2.2. PCR-based Molecular Assays
  - 4.2.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.2.3. Real-time PCR
  - 4.2.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.2.4. Sequence-based Primer-PCR
  - 4.2.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.2.5. Sequence-specific Oligonucleotide-PCR
- 4.2.6. Other PCR-based Molecular Assays
  - 4.2.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.3. Sequencing-based Molecular Assays
- 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.3.2. Sanger Sequencing
  - 4.3.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.3.3. Next Generation Sequencing
  - 4.3.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.3.4. Other Sequencing-based Molecular Assays
  - 4.3.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4. Non-molecular Assays
- 4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4.2. Serological Assays
  - 4.4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4.3. Mixed Lymphocyte Culture Assays
  - 4.4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Transplant Diagnostics Market: Product Estimates & Trend Analysis

5.1. Transplant Diagnostics Market: Product Movement Analysis
5.2. Reagents & Consumables
- 5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.3. Instruments
- 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4. Software and Services
- 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Transplant Diagnostics Market: Application Estimates & Trend Analysis

6.1. Transplant Diagnostics Market: Application Movement Analysis
6.2. Diagnostic Application
- 6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.2.2. Infectious Disease Testing
  - 6.2.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.2.3. Histocompatibility Testing
  - 6.2.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.2.4. Blood Profiling
6.3. Research Application
- 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Transplant Diagnostics Market: Transplant Area Estimates & Trend Analysis

7.1. Transplant Diagnostics Market: Transplant Area Movement Analysis
7.2. Solid Area Transplantation
- 7.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.2.2. Kidney Transplantation
  - 7.2.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.2.3. Liver Transplantation
  - 7.2.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.2.4. Heart Transplantation
  - 7.2.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.2.5. Lung Transplantation
  - 7.2.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.2.6. Pancreas Transplantation
  - 7.2.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.2.7. Other Organs Transplantation
  - 7.2.7.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.3. Stem Cell Transplantation
- 7.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.2. Soft Tissue Transplantation
  - 7.3.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.3. Bone Marrow Transplantation
  - 7.3.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Transplant Diagnostics Market: End Use Estimates & Trend Analysis

8.1. Transplant Diagnostics Market: End Use Movement Analysis
8.2. Hospitals and Transplant Centers
- 8.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
8.3. Research and Academic Institutes
- 8.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
8.4. Independent Reference Laboratories
- 8.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Transplant Diagnostics Market: Regional Business Analysis

9.1. Regional Market Snapshot
9.2. North America
- 9.2.1. North America Transplant Diagnostics Market Estimates And Forecast, 2021 - 2033 (USD Million)
- 9.2.2. U.S.
  - 9.2.2.1. U.S. Transplant Diagnostics Market, 2021 - 2033 (USD Million)
  - 9.2.2.2. Key Country Dynamics
  - 9.2.2.3. Regulatory Framework
  - 9.2.2.4. Reimbursement Scenario
  - 9.2.2.5. Competitive Scenario
- 9.2.3. Canada
  - 9.2.3.1. Canada Transplant Diagnostics Market, 2021 - 2033 (USD Million)
  - 9.2.3.2. Key Country Dynamics
  - 9.2.3.3. Regulatory Framework
  - 9.2.3.4. Reimbursement Scenario
  - 9.2.3.5. Competitive Scenario
- 9.2.4. Mexico
  - 9.2.4.1. Mexico Transplant Diagnostics Market, 2021 - 2033 (USD Million)
  - 9.2.4.2. Key Country Dynamics
  - 9.2.4.3. Regulatory Framework
  - 9.2.4.4. Reimbursement Scenario
  - 9.2.4.5. Competitive Scenario
9.3. Europe
- 9.3.1. Europe Transplant Diagnostics Market, 2021 - 2033 (USD Million)
- 9.3.2. UK
  - 9.3.2.1. UK Transplant Diagnostics Market, 2021 - 2033 (USD Million)
  - 9.3.2.2. Key Country Dynamics
  - 9.3.2.3. Regulatory Framework
  - 9.3.2.4. Reimbursement Scenario
  - 9.3.2.5. Competitive Scenario
- 9.3.3. Germany
  - 9.3.3.1. Germany Transplant Diagnostics Market, 2021 - 2033 (USD Million)
  - 9.3.3.2. Key Country Dynamics
  - 9.3.3.3. Regulatory Framework
  - 9.3.3.4. Reimbursement Scenario
  - 9.3.3.5. Competitive Scenario
- 9.3.4. Spain
  - 9.3.4.1. Spain Transplant Diagnostics Market, 2021 - 2033 (USD Million)
  - 9.3.4.2. Key Country Dynamics
  - 9.3.4.3. Regulatory Framework
  - 9.3.4.4. Reimbursement Scenario
  - 9.3.4.5. Competitive Scenario
- 9.3.5. France
  - 9.3.5.1. France Transplant Diagnostics Market, 2021 - 2033 (USD Million)
  - 9.3.5.2. Key Country Dynamics
  - 9.3.5.3. Regulatory Framework
  - 9.3.5.4. Reimbursement Scenario
  - 9.3.5.5. Competitive Scenario
- 9.3.6. Italy
  - 9.3.6.1. Italy Transplant Diagnostics Market, 2021 - 2033 (USD Million)
  - 9.3.6.2. Key Country Dynamics
  - 9.3.6.3. Regulatory Framework
  - 9.3.6.4. Reimbursement Scenario
  - 9.3.6.5. Competitive Scenario
- 9.3.7. Denmark
  - 9.3.7.1. Denmark Transplant Diagnostics Market, 2021 - 2033 (USD Million)
  - 9.3.7.2. Key Country Dynamics
  - 9.3.7.3. Regulatory Framework
  - 9.3.7.4. Reimbursement Scenario
  - 9.3.7.5. Competitive Scenario
- 9.3.8. Sweden
  - 9.3.8.1. Sweden Transplant Diagnostics Market, 2021 - 2033 (USD Million)
  - 9.3.8.2. Key Country Dynamics
  - 9.3.8.3. Regulatory Framework
  - 9.3.8.4. Reimbursement Scenario
  - 9.3.8.5. Competitive Scenario
- 9.3.9. Norway
  - 9.3.9.1. Norway Transplant Diagnostics Market, 2021 - 2033 (USD Million)
  - 9.3.9.2. Key Country Dynamics
  - 9.3.9.3. Regulatory Framework
  - 9.3.9.4. Reimbursement Scenario
  - 9.3.9.5. Competitive Scenario
9.4. Asia Pacific
- 9.4.1. Asia-Pacific Transplant Diagnostics Market, 2021 - 2033 (USD Million)
- 9.4.2. Japan
  - 9.4.2.1. Japan Transplant Diagnostics Market, 2021 - 2033 (USD Million)
  - 9.4.2.2. Key Country Dynamics
  - 9.4.2.3. Regulatory Framework
  - 9.4.2.4. Reimbursement Scenario
  - 9.4.2.5. Competitive Scenario
- 9.4.3. China
  - 9.4.3.1. China Transplant Diagnostics Market, 2021 - 2033 (USD Million)
  - 9.4.3.2. Key Country Dynamics
  - 9.4.3.3. Regulatory Framework
  - 9.4.3.4. Reimbursement Scenario
  - 9.4.3.5. Competitive Scenario
- 9.4.4. India
  - 9.4.4.1. India Transplant Diagnostics Market, 2021 - 2033 (USD Million)
  - 9.4.4.2. Key Country Dynamics
  - 9.4.4.3. Regulatory Framework
  - 9.4.4.4. Reimbursement Scenario
  - 9.4.4.5. Competitive Scenario
- 9.4.5. South Korea
  - 9.4.5.1. South Korea Transplant Diagnostics Market, 2021 - 2033 (USD Million)
  - 9.4.5.2. Key Country Dynamics
  - 9.4.5.3. Regulatory Framework
  - 9.4.5.4. Reimbursement Scenario
  - 9.4.5.5. Competitive Scenario
- 9.4.6. Thailand
  - 9.4.6.1. Thailand Transplant Diagnostics Market, 2021 - 2033 (USD Million)
  - 9.4.6.2. Key Country Dynamics
  - 9.4.6.3. Regulatory Framework
  - 9.4.6.4. Reimbursement Scenario
  - 9.4.6.5. Competitive Scenario
- 9.4.7. Australia
  - 9.4.7.1. Australia Transplant Diagnostics Market, 2021 - 2033 (USD Million)
  - 9.4.7.2. Key Country Dynamics
  - 9.4.7.3. Regulatory Framework
  - 9.4.7.4. Reimbursement Scenario
  - 9.4.7.5. Competitive Scenario
9.5. Latin America
- 9.5.1. Latin America Transplant Diagnostics Market, 2021 - 2033 (USD Million)
- 9.5.2. Brazil
  - 9.5.2.1. Brazil Transplant Diagnostics Market, 2021 - 2033 (USD Million)
  - 9.5.2.2. Key Country Dynamics
  - 9.5.2.3. Regulatory Framework
  - 9.5.2.4. Reimbursement Scenario
  - 9.5.2.5. Competitive Scenario
- 9.5.3. Argentina
  - 9.5.3.1. Argentina Transplant Diagnostics Market, 2021 - 2033 (USD Million)
  - 9.5.3.2. Key Country Dynamics
  - 9.5.3.3. Regulatory Framework
  - 9.5.3.4. Reimbursement Scenario
  - 9.5.3.5. Competitive Scenario
9.6. MEA
- 9.6.1. MEA Transplant Diagnostics Market, 2021 - 2033 (USD Million)
- 9.6.2. South Africa
  - 9.6.2.1. South Africa Transplant Diagnostics Market, 2021 - 2033 (USD Million)
  - 9.6.2.2. Key Country Dynamics
  - 9.6.2.3. Regulatory Framework
  - 9.6.2.4. Reimbursement Scenario
  - 9.6.2.5. Competitive Scenario
- 9.6.3. Saudi Arabia
  - 9.6.3.1. Saudi Arabia Transplant Diagnostics Market, 2021 - 2033 (USD Million)
  - 9.6.3.2. Key Country Dynamics
  - 9.6.3.3. Regulatory Framework
  - 9.6.3.4. Reimbursement Scenario
  - 9.6.3.5. Competitive Scenario
- 9.6.4. UAE
  - 9.6.4.1. UAE Transplant Diagnostics Market, 2021 - 2033 (USD Million)
  - 9.6.4.2. Key Country Dynamics
  - 9.6.4.3. Regulatory Framework
  - 9.6.4.4. Reimbursement Scenario
  - 9.6.4.5. Competitive Scenario
- 9.6.5. Kuwait
  - 9.6.5.1. Kuwait Transplant Diagnostics Market, 2021 - 2033 (USD Million)
  - 9.6.5.2. Key Country Dynamics
  - 9.6.5.3. Regulatory Framework
  - 9.6.5.4. Reimbursement Scenario
  - 9.6.5.5. Competitive Scenario

Chapter 10. Competitive Landscape

10.1. Company Categorization
10.2. Strategy Mapping
- 10.2.1. New product launch
- 10.2.2. Partnerships
- 10.2.3. Acquisition
- 10.2.4. Collaboration
- 10.2.5. Funding
10.3. Key Company Market Share Analysis, 2024
10.4. Company Heat Map Analysis
10.5. Company Profiles
- 10.5.1. Thermo Fisher Scientific, Inc.
  - 10.5.1.1. Company Overview
  - 10.5.1.2. Financial Performance
  - 10.5.1.3. Product Benchmarking
  - 10.5.1.4. Strategic Initiatives
- 10.5.2. Illumina, Inc.
  - 10.5.2.1. Company Overview
  - 10.5.2.2. Financial Performance
  - 10.5.2.3. Product Benchmarking
  - 10.5.2.4. Strategic Initiatives
- 10.5.3. F. Hoffmann La-Roche Ltd
  - 10.5.3.1. Company Overview
  - 10.5.3.2. Financial Performance
  - 10.5.3.3. Product Benchmarking
  - 10.5.3.4. Strategic Initiatives
- 10.5.4. Abbott
  - 10.5.4.1. Company Overview
  - 10.5.4.2. Financial Performance
  - 10.5.4.3. Product Benchmarking
  - 10.5.4.4. Strategic Initiatives
- 10.5.5. QIAGEN
  - 10.5.5.1. Company Overview
  - 10.5.5.2. Financial Performance
  - 10.5.5.3. Product Benchmarking
  - 10.5.5.4. Strategic Initiatives
- 10.5.6. Bruker
  - 10.5.6.1. Company Overview
  - 10.5.6.2. Financial Performance
  - 10.5.6.3. Product Benchmarking
  - 10.5.6.4. Strategic Initiatives
- 10.5.7. BD (Becton, Dickinson and Company)
  - 10.5.7.1. Company Overview
  - 10.5.7.2. Financial Performance
  - 10.5.7.3. Product Benchmarking
  - 10.5.7.4. Strategic Initiatives
- 10.5.8. Werfen (Immucor, Inc.)
  - 10.5.8.1. Company Overview
  - 10.5.8.2. Financial Performance
  - 10.5.8.3. Product Benchmarking
  - 10.5.8.4. Strategic Initiatives
- 10.5.9. Bio-Rad Laboratories, Inc.
  - 10.5.9.1. Company Overview
  - 10.5.9.2. Financial Performance
  - 10.5.9.3. Product Benchmarking
  - 10.5.9.4. Strategic Initiatives
- 10.5.10. Omixon Inc.
  - 10.5.10.1. Company Overview
  - 10.5.10.2. Financial Performance
  - 10.5.10.3. Product Benchmarking
  - 10.5.10.4. Strategic Initiatives